Genetically Engineered Mesenchymal Stem Cells Influence Gene Expression in Donor Cardiomyocytes and the Recipient Heart.
Authors:
Journal: Journal of stem cell research & therapy
Publication Type: Journal Article
Date: 2012
DOI: NIHMS402223
ID: 23125947
Abstract
AIMS: Human embryonic stem cell-derived cardiomyocytes (hESC-CMs) or mesenchymal stem cells (MSCs) facilitate post-infarct recovery, but the potential benefit of combination therapy using MSCs and hESC-CMs has not been examined. Our objective was to define the gene expression changes in donor and host-derived cells that are induced in vivo after co-transplantation of cardiomyocytes with and without mesenchymal stem cells expressing the prosurvival gene heme oxygenase 1. METHODS AND RESULTS: Human MSCs were engineered to over-express heme oxygenase-1 (HO-1) following lentiviral vector-mediated transduction. Athymic nude rats were subjected to myocardial infarction and received hESC-CMs alone, hESC-CMs plus human MSCs, hESC-CMs plus MSCs overexpressing HO-1, or saline. Real time PCR identified gene expression changes. Cardiac function was assessed by angiography. Co-transplantation of unmodified MSCs plus hESC-CMs elevated CXCR4, HGF, and IGF expression over levels induced by injection of hESC-derived cardiomyocytes alone. In animals co-transplanted with MSC over-expressing HO-1, the expression of these genes was further elevated. Gene expression levels of VEGF, TGF-β, CCL2, SMAD7, STAT3 and cardiomyocyte transcription factors were highest in the HO-1 MSC plus hESC-CM group at 30 days. Human CD31+, CD34+, isl-1+, NXK2.5 and c-kit+ transcripts were elevated. Rodent genes encoding NKX2.5, troponin T and CD31 were elevated and cell cycle genes were induced. Ejection fraction improved by six to seven percent. CONCLUSIONS: Co-administration of HO-1 MSCs plus hESC-CMs increased expression of pro-survival and angiogenesis-promoting genes in human cells and transcripts of cardiac and endothelial cell markers in rodent cells, consistent with activation of tissue repair in both transplanted hESC-CMs and the host heart.
Reference List
- Kearns-Jonker M, Dai W, Kloner RA. Stem Cells for the Treatment of Heart Failure. Curr Opin Mol Ther. 2010;12:432–441.|||Mummery CL, Davis RP, Krieger JE. Challenges in using stem cells for cardiac repair. Sci Transl Med. 2010;2:27.|||Fernandes S, Naumova AV, Zhu WZ, Laflamme MA, Gold J, et al. Human embryonic stem cell-derived cardiomyocytes engraft but do not alter cardiac remodeling after chronic infarction in rats. J Mol Cell Cardiol. 2010;49:941–949.|||Gnecchi M, He H, Liang OD, Melo LG, Morello F, et al. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med. 2005;11:367–368.|||Tang YL, Tang Y, Zhang YC, Qian K, Shen L, et al. Improved graft mesenchymal stem cell survival in ischemic heart with a hypoxia-regulated heme-oxygenase 1 vector. J Am Coll Cardiol. 2005;46:1339–1350.|||Zeng B, Chen H, Zhu C, Ren X, Lin G, et al. Effects of combined mesenchymal stem cells and heme oxygenase-1 therapy on cardiac performance. Eur J Cardiothorac Surg. 2008;34:850–856.|||Zeng B, Lin G, Ren X, Zhang Y, Chen H. Over-expression of HO-1 on mesenchymal stem cells promotes angiogenesis and improves myocardial function in infarcted myocardium. J Biomed Sci. 2010;17:80.|||Tsubokawa T, Yagi K, Nakanishi C, Zuka M, Nohara A, et al. Impact of anti-apoptotic and anti-oxidative effects of bone marrow mesenchymal stem cells with transient overexpression of heme oxygenase-1 on myocardial ischemia. Am J Physiol Heart Circ Physiol. 2010;298:H1320–H1329.|||Laflamme M, Chen KY, Naumova AV, Muskheli V, Fugate JA, et al. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat Biotechnol. 2007;25:1015–1024.|||Okada H, Takemura G, Kosai K, Tsujimoto A, Esaki M, et al. Combined therapy with cardioprotective cytokine administration and antiapoptotic gene transfer in postinfarction heart failure. Am J Physiol Heart Circ Physiol. 2009;296:H616–H626.|||Winter EM, van Oorschot AA, Hogers B, van der Graaf LM, Doevendans PA, et al. A new direction for cardiac regeneration therapy: application of synergistically acting epicardium-derived cells and cardiomyocyte progenitor cells. Circ Heart Fail. 2009;2:643–653.|||Zeng B, Ren X, Lin G, Zhu C, Chen H, et al. Paracrine action of HO-1- modified mesenchymal stem cells mediates cardiac protection and functional improvement. Cell Biol Int. 2008;32:1256–1264.|||Lin HH, Chen YH, Chang PF, Lee YT, Yet SF, et al. Heme oxygenase-1 promotes neovascularization in ischemic heart by coinduction of VEGF and SDF-1. J Mol Cell Cardiol. 2008;45:44–55.|||Lakkisto P, Kytö V, Forsten H, Siren JM, Segersvärd H, et al. Heme oxygenase-1 and carbon monoxide promote neovascularization after myocardial infarction by modulating the expression of HIF-1alpha, SDF-1alpha and VEGF-B. Eur J Pharmacol. 2010;635:156–164.|||Wu BJ, Midwinter RG, Cassano C, Beck K, Wang Y, et al. Heme oxygenase-1 increases endothelial progenitor cells. Arterioscler Thromb Vasc Biol. 2009;29:1537–1542.|||Wang G, Hamid T, Keith RJ, Zhou G, Partridge CR, et al. Cardioprotective and antiapoptotic effects of heme oxygenase-1 in the failing heart. Circulation. 2010;121:1912–1925.|||Lin HH, Chen YH, Yet SF, Chau LY. After vascular injury, heme oxygenase-1/carbon monoxide enhances re-endothelialization via promoting mobilization of circulating endothelial progenitor cells. J Thromb Haemost. 2009;7:1401–1408.|||Pachori AS, Smith A, McDonald P, Zhang L, Dzau VJ, et al. Heme-oxygenase-1-induced protection against hypoxia/reoxygenation is dependent on biliverdin reductase and its interaction with PI3K/Akt pathway. J Mol Cell Cardiol. 2007;43:580–592.|||Yamashita K, Ollinger R, McDaid J, Sakahama H, Wang H, et al. Heme oxygenase-1 is essential for and promotes tolerance to transplanted organs. FASEB J. 2006;20:776–778.|||Tongers J, Knapp JM, Korf M, Kempf T, Limbourg A, et al. Heme oxygenase promotes progenitor cell mobilization, neovascularization, and functional recovery after critical hindlimb ischaemia in mice. Cardiovasc Res. 2008;78:294–300.|||Passier R, Oostwaard DW, Snapper J, Kloots J, Hassink RJ, et al. Increased cardiomyocyte differentiation from human embryonic stem cells in serum-free cultures. Stem Cells. 2005;23:772–780.|||Mummery C, Ward-van Oostward D, Doevendans P, Spijker R, van den Brink S, et al. Differentiation of human embryonic stem cells to cardiomyocytes: role of coculture with visceral endoderm-like cells. Circulation. 2003;107:2733–2740.|||Kehat I, Khimovich L, Caspi O, Gepstein A, Shofti R, et al. Electromechanical integration of cardiomyocytes derived from human embryonic stem cells. Nat Biotechnol. 2004;22:1282–1289.|||von Levetzow C, Jiang X, Gwye Y, von Levetzow G, Hung L, et al. Modeling initiation of Ewing sarcoma in human neural crest cells. PLoS One. 2011;6:e19305.|||Dai W, Hale S, Kloner RA. Role of a paracrine action of mesenchymal stem cells in the improvement of left ventricular function after coronary artery occlusion in rats. Regen Med. 2007;2:63–68.|||Dai W, Hale SL, Martin BJ, Kuang JQ, Dow JS, et al. Allogeneic mesenchymal stem cell transplantation in postinfarcted rat myocardium. Short- and long- term effects. Circulation. 2005;112:214–223.|||Evans JM, Doki T, Fischer-Lougheed J, Davicioni E, Kearns-Jonker M. Expression changes in tolerant murine cardiac allografts after gene therapy with a lentiviral vector expressing α1,3 galactosyltransferase. Transplant Proc. 2006;38:3172–3180.|||Doki T, Mello M, Mock D, Evans JM, Kearns-Jonker M. Intragraft gene expression profile associated with the induction of tolerance. BMC Immunology. 2008;9:5.|||Hochman JS, Choo H. Limitation of myocardial infarct expansion by reperfusion independent of myocardial salvage. Circulation. 1987;75:299–306.|||Enoki C, Otani H, Sato D, Okada T, Hattori R, et al. Enhanced mesenchymal cell engraftment by IGF-1 improves left ventricular function in rats undergoing myocardial infarction. Int J Cardiol. 2010;138:9–18.|||Penn MS, Agarwal U. IGF-1 and mechanisms of myocardial repair. Int J Cardiol. 2010;138:1–2.|||Schober A, Karshovska E, Zernecke A, Weber C. SDF-1alpha-mediated tissue repair by stem cells: a promising tool in cardiovascular medicine? Trends Cardiovasc Med. 2006;16:103–108.|||Yin Q, Jin P, Liu X, Wei H, Lin X, et al. SDF-1α inhibits hypoxia and serum deprivation-induced apoptosis in mesenchymal stem cells through PI3K/ Akt and ERK1/2 signaling pathways. Mol Biol Rep. 2011;38:9–16.|||Unzek S, Zhang M, Mal N, Mills WR, Laurita KR, et al. SDF-1 recruits cardiac stem cell-like cells that depolarize in vivo. Cell Transplant. 2007;16:879–886.|||Penn MS. Importance of the SDF-1:CXCR4 axis in myocardial repair. Circ Res. 2009;104:1133–1135.|||Chiriac A, Terzic A, Park S, Ikeda Y, Faustino R, et al. SDF-1-enhanced cardiogenesis requires CXCR4 induction in pluripotent stem cells. J Cardiovasc Transl Res. 2010;3:674–682.|||Moretti A, Caron L, Nakano A, Lam JT, Bernshausen A, et al. Multipotent embryonic isl1+ progenitor cells lead to cardiac, smooth muscle, and endothelial cell diversification. Cell. 2006;127:1151–1165.|||Hatzistergos KE, Quevedo H, Oskouei BN, Hu Q, Feigenbaum GS, et al. Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation. Circ Res. 2010;107:913–922.|||Zaruba MM, Soonpa MM, Reuter S, Field LJ. Cardiomyogenic potential of c-kit+ expressing cells derived from neonatal and adult mouse hearts. Circulation. 2010;121:1992–2000.|||Nourse MB, Halpin DE, Scatena M, Mortisen DJ, Tulloch N, et al. VEGF induces differentiation of functional endothelium from human embryonic stem cells. Arterioscler Thromb Vasc Biol. 2010;30:80–89.|||Lin HH, Lai SC, Chau LY. Heme oxygenase-1/carbon monoxide induces vascular endothelial growth factor expression via p38 kinase-dependent activation of Sp1. J Biol Chem. 2011;286:3829–3838.|||Kitabayashi K, Siltanen A, Pätilä T, Mahar MA, Tikkanen I, et al. Bcl-2 expression enhances myoblast sheet transplantation therapy for acute myocardial infarction. Cell Transplant. 2010;19:573–588.|||Kutschka I, Kolfidis T, Chen IY, von Degenfeld G, Zwierzchoniewska M, et al. Adenoviral human Bcl2 transgene expression attenuates early donor cell death after cardiomyoblast transplantation into ischemic rat hearts. Circulation. 2006;114:I174–I180.|||Souza AI, Felkin LE, McCormack AM, Holder A, Barton PJ, et al. Sequential expression of three known protective genes in cardiac biopsies after transplantation. Transplantation. 2005;79:584–590.|||Tang XL, Rokosh G, Sanganalmath SK, Yuan F, Sato H, et al. Intracoronary administration of cardiac progenitor cells alleviates left ventricular dysfunction in rats with a 30-day-old infarction. Circulation. 2010;121:293–305.|||Loffredo F, Steinhauser M, Gannon J, Lee RT. Bone marrow–derived cell therapy stimulates endogenous cardiomyocyte progenitors and promotes cardiac repair. Cell Stem Cell. 2011;8:389–398.|||Chen Q, Chen H, Zheng D, Kuang C, Fang H, et al. Smad7 is required for the development and function of the heart. J Biol Chem. 2009;284:292–300.|||Kroeze KL, Jurgens WJ, Doulabi BZ, van Milligen FJ, Scheper RJ, et al. Chemokine-mediated migration of skin-derived stem cells: predominant role for CCL5/RANTES. J Invest Dermatol. 2009;129:1569–1581.|||Li JQ, Qi HZ, He ZJ, Hu W, Si ZZ, et al. Cytoprotective effects of human interleukin-10 gene transfer against necrosis and apoptosis induced by hepatic cold ischemia/reperfusion injury. J Surg Res. 2009;157:e71–e78.|||Krishnamurthy P, Rajasingh J, Lambers E, Qin G, Losordo DW, et al. IL-10 inhibits inflammation and attenuates left ventricular remodeling after myocardial infarction via activation of STAT3 and suppression of HuR. Circ Res. 2009;104:e9–e18.